Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PPP005 (high CBD with trace THC)
- Development stage
- Phase 3
- Lead developer
- Tetra Bio-Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PPP005 is a medical cannabis oil formulation developed by Santé Cannabis (formerly Tetra Bio-Pharma) for the management of chronic pain, including both cancer-related and chronic non-cancer pain. This specific formulation is characterized by a high concentration of cannabidiol (CBD) with only trace amounts of tetrahydrocannabinol (THC), delivered as an encapsulated oil designed to meet pharmaceutical standards. The drug acts through the endocannabinoid system and other pain-related pathways; CBD serves as a negative allosteric modulator of CB1 and CB2 receptors and an agonist at TRPV1 and 5-HT1A receptors, providing analgesic, anti-inflammatory, and anxiolytic effects. The trace THC component provides synergistic therapeutic benefits with minimal psychoactive impact. PPP005 was evaluated in Phase 2 clinical trials to assess its safety, efficacy, and potential as an opioid-sparing treatment for patients whose pain was inadequately controlled by conventional prescriptions.
- Other names
- high CBD with trace THC oilmedical cannabis oil
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on PPP005 (high CBD with trace THC).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PPP005 (high CBD with trace THC).